AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational ...

The $2.5 billion investment reflects AstraZeneca's continued commitment to China, Chief Executive Pascal Soriot said. The R&D facility will be the company's second in China, coming after its research ...

AstraZeneca (AZN) stock in focus as the company invests $2.5B in Beijing for a new R&D center, strengthening its footprint in ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development ...

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

Pandemic influenza remains a significant global health threat, as signalled by the circulation and cross-species transmission of avian influenza A(H5N1) viruses from the clade 2.3.4.4b, including ...

The National Institutes of Health, which falls under the jurisdiction of HHS, has terminated grants for research into vaccine ...

New inhaled COVID-19 vaccine by McMaster enters phase-2 trials in Canada. The vaccine aims to provide stronger, needle-free ...

Five years ago, on March 11, the World Health Organization declared COVID-19 a global pandemic. The vaccines “underwent the most intensive safety analysis in U.S. history." ...